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Grant Cave1* and Martyn G Harvey2Abstract
The use of intravenous lipid emulsions (ILEs) as
antidote in local anaesthetic systemic toxicity has
gained widespread support following convincing data
from animal models, and successful case reports in
humans. Proposed beneficial mechanisms of action
for ILEs include intravascular sequestration of
intoxicant and subsequent enhanced redistribution to
biologically inert tissues, augmentation of fatty acid
utilisation for ATP synthesis in the context of
metabolic poisoning, and direct cardiotonic and ion
channel effects. The evidence base for use of ILEs in
acute drug intoxication is evolving. The present
evidence supports use of ILEs only in local anaesthetic
systemic toxicity and in lipophilic cardiotoxin
intoxication when there is an immediate threat to life,
and other therapies have proven ineffective.circulation and survived to hospital discharge. These, the
first case reports of successful ILE use in local anaestheticIntroduction
Intravenous lipid emulsion (ILE) has a long history of use
as a parenteral nutrition formulation in both adult and
paediatric patients. Over the past decade, ILE also emerged
as a novel treatment for iatrogenic and intentional drug
poisonings. Progress from nutritional replacement to anti-
dote has been rapid, necessitating regular review of the ra-
tionale and evidence base for administration.
As early as 1998 Weinberg and colleagues reported at-
tenuation of bupivacaine toxicity in a rat model [1], fol-
lowing a chance finding while attempting to replicate
local anaesthetic effects in disorders of carnitine metab-
olism. These findings were subsequently confirmed in
intact dogs [2]. Still earlier findings of lipid modulation
of free drug concentrations have been reported as far
back as 1974 [3]. Promising laboratory studies such as* Correspondence: grantcave@gmail.com
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reproduction in any medium, provided the orthese may have forever lacked clinical impact but for
two sentinel cases of ILE use in human poisoning.
In 2006 Rosenblatt and colleagues [4] reported success-
ful resuscitation with ILE following bupivacaine and
mepivacaine-induced cardiac arrest in a middle aged man
undergoing brachial plexus block. Prior treatment with
advanced cardiac life support, defibrillation, and multiple
doses of vasopressor and antiarryhthmic medications had
failed to effect return of spontaneous circulation. Normal
sinus rhythm was nevertheless restored following one
100 ml bolus of ILE with rapid return of haemodynamic
stability. The patient was discharged neurologically intact.
Likewise in 2007, Sirianni and colleagues [5] published a
case of overwhelming bupropion and lamotrigine self poi-
soning in a 17 year old girl. Cardiovascular collapse refrac-
tory to standard resuscitative measures persisted for
70 minutes before administration of 100 ml ILE. Immedi-
ately after injection the patient exhibited a sustained stable
systemic toxicity (LAST) and non-local anaesthetic intoxi-
cation, respectively, are unique for a number of reasons.
In both instances attending physicians were presented
with desperate and apparently irretrievable clinical scenar-
ios secondary to poisoning. The decision to employ ILE
was made late in the course of resuscitative attempts as a
‘last gasp’ measure, with only limited animal data to sup-
port utilisation. And, in both circumstances, use was asso-
ciated with dramatic success and patient survival.
The dissemination of these and other subsequent cases
of clinical use of ILE has seen ILE make the transition
from bench-top modelling to clinically utilised antidote
without the evidence base commonly associated with
introduction of newly formulated drugs. There have
been many recent systematic reviews on this topic of a
high standard [6-10]. It is the purpose of the present
narrative review to examine recent literature with a par-
ticular focus on advances in understanding of the mech-
anism of ILE, and to evaluate the evidence supporting
ILE administration, and thereby establish whether anyntral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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warranted. PubMed was searched for the 5 years since
the authors previous review [6], using the search terms
intravenous AND fat emulsion OR lipid emulsion OR
intralipid AND "toxicity" OR "resuscitation" OR "rescue"
OR "arrest" OR "antidote" and a filter for relevance. Only
English language papers were included.
Rationale for use of intravenous lipid emulsion in
toxicology
There are presently four small human trials involving the
use of ILE: one clinical randomised controlled trial of lim-
ited methodologic quality, one case–control study and
two pharmacokinetic evaluations. While this small body
of human trial work is of importance, it is not sufficient to
form a view on the use of ILE in toxicology. The weight of
present data is in benchtop and animal models and col-
lated human case reports. While it is possible to evaluate
such an evidence base, there are clear limits to the breadth
such evidence can generalise to everyday clinical practice.
In the setting of immediate threat to life where other
treatments are not proving effective, it is reasonable to
use an agent when there is an established rationale for
use and 'all or nothing' cases such as those described
above have been reported. Table 1 lists agents for which
the criterion of positive benchtop evidence and reported
clinical use associated with a positive outcome has been
fulfilled.Table 1 Agents for which there is both positive benchtop
evidence for class effect and reported clinical use








Flecainide (benchtop model evidence equivocal)
Propafenone
Cocaine








HaloperidolGiven the above rationale, this paper first outlines the
available laboratory evidence on mechanism of action of
ILE as antidote, and then progresses to review reported
clinical experience.
Pharmacologic mechanism of action for
intravenous lipid emulsion
Knowledge of the proposed pharmacologic mechanisms
of action of ILE in acute intoxication is important when
considering clinical application. Despite extensive and
ongoing study the precise mode of action for ILE in
many poisonings remains to be fully elucidated. At
present both pharmacokinetic and pharmacodynamic ac-
tions have been postulated to play a role in the action of
ILE as antidote. Whilst synergy between proposed ac-
tions may exist, the relative contributions of each remain
uncertain. It is quite possible that each mechanism may
variably contribute to clinically observed improvement
depending on unique combinations of patient factors,
the mode and duration since poisoning, and the particu-
lar intoxicant.
Pharmacokinetic modulation/lipid sink theory
First forwarded by Weinberg in 1998 [1], this hypothesis
proposes that, following ILE injection, lipophilic intoxi-
cant preferentially distributes into the newly created
intravascular lipid compartment, and is held away from
the site of toxic action. The hypothesis has been ex-
tended to include effects on subsequent enhanced redis-
tribution of lipophilic intoxicants, with increased blood
carriage thought to speed transport of toxin from target
organ to peripheral adipose tissue depots. This so called
‘lipid sink’ thesis has served to guide much of the early
development of ILE therapy, with the majority of agents
studied thus far exhibiting high lipid solubility.
Evidence in support of the lipid sink has been derived
from both pre-clinical models and human reports. Fol-
lowing their study with the prototypical lipophilic local
anaesthetic bupivacaine in whole rat models of cardio-
toxicity [1], Weinberg and colleagues subsequently dem-
onstrated enhanced myocardial washout of bupivacaine
when cardiac perfusate was spiked with ILE in an iso-
lated heart model [11]. Both greater myocardial bupiva-
caine loss (P < 0.0016) and increased coronary sinus
effluent bupivacaine concentration (P < 0.008) were re-
corded, in keeping with rapid tissue detoxification. Simi-
larly, Chen and colleagues [12] have shown lesser
myocardial bupivacaine concentrations, and associated
dose-dependent increases in rate-pressure product for
isolated rat hearts subjected to lipid emulsion.
Subsequent authors investigating the effect of ILE in-
jection in whole rats have demonstrated evidence of en-
hanced drug redistribution with reduced bupivacaine
concentration in heart, brain, lung, kidney and splenic
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atic bupivacaine concentration was increased. In this
model ILE use was associated with greater bupivacaine
clearance, and prolonged half-life (T1/2) compared with
control animals, in keeping with favourable modulation
to bupivacaine pharmacokinetics.
Support for a lipid sink effect is not confined to lipo-
philic local anaesthetics, with animal models and human
cases demonstrating an effect with a range of disparate
intoxicants, including calcium channel blockers [25-27],
lipophilic beta-blockers [28,29], tricyclic antidepressants
[15-17], antipsychotics [30,31], and antiarrhythmics [32].
Despite lacking commonality in their toxicodynamic mech-
anisms, agents demonstrating response to ILE treatment
typically exhibit high lipid solubility (log D (octanol:water
partition coefficient at physiologic pH) >2; bupivacaine
logD = 3.65), consistent with the proposed pharmacoki-
netic mechanism. Indeed, drug partitioning constants and
volumes of distribution have been investigated as predic-
tors of ILE responsiveness. French and co-workers in 2011
[33] demonstrated in vitro sequestration of lipophilic drugs
in human plasma spiked with lipid emulsion, and subse-
quently assembled a compendium of predicted lipid extrac-
tion efficiency on the basis of the intrinsic pharmacologic
parameters for over 50 commonly used drugs.
In vivo studies using non-local anaesthetic drugs have
confirmed sink effects in intact animal models and hu-
man subjects. In a rabbit model of intravenous clomipra-
mine toxicity, increased total blood concentrations of
clomipramine were seen in concert with improved blood
pressure following ILE injection, consistent with seques-
tration of toxin into an intravascular lipid phase [34].
Litonius and colleagues [35] similarly demonstrated an
increased total amitriptyline concentration with a de-
crease in free amitriptyline fraction in amitriptyline toxic
pigs when ILE was given after amitriptyline infusion.
Notably, however, there was no improvement seen in
haemodynamic metrics nor survival in this model. The
same group furthermore demonstrated that pretreat-
ment with ILE improved haemodynamics during an ami-
odarone infusion, and resulted in increased amiodarone
total concentration and decreased free drug concen-
tration [32]. ILE has also been shown to reduce brain
concentrations of amitriptyline when given following
intravenous infusion and tissue distribution time in
swine [36]. In the same experiment a non-statistically
significant reduction in cardiac amitriptyline concentra-
tions was additionally reported (P = 0.07).
Human pharmacokinetic data are limited to two clinical
studies and sporadic case reports. Minton and colleagues
[37] demonstrated a statistically non-significant increase in
plasma amitriptyline concentrations in subjects in pharma-
cokinetic steady state subjected to infused lipid emulsion.
Free drug concentrations were not measured. Litonius andcolleagues [38] furthermore found a decreased half-life for
a nontoxic dose of bupivacaine in blood after administra-
tion of ILE in eight normal subjects, consistent with an ef-
fect on tissue redistribution. A decrease in free verapamil
concentration was reported after treatment with ILE for in-
toxication [39], commensurate with clinical improvement.
In another report, increased total blood amitriptyline con-
centrations were seen following ILE therapy in a case of
mixed overdose with prominent tricyclic toxidrome [40].
While attractive in its simplicity, emerging evidence sug-
gests application of the sink theory must be approached
with some caution in all but a few overdose scenarios. A
pure sink effect may be important in cardiac arrest due to
direct intravenous bolus administration of intoxicant - the
centralised circulation meaning that rapid equilibration of
heart and brain concentrations with the introduced, cen-
trally confined lipid phase may be possible. Subsequent re-
distribution of intoxicant to peripheral fat depots on
return of effective circulation would conceivably ensue -
such a situation could be hypothesized to occur in most
forms of LAST.
Any pharmacokinetic effect for ILE in the non-arrested
patient likely depends on both the pharmacokinetic phase
and circulatory status at the time of intoxication. In-
creased plasma carriage for lipophilic toxins with ILE
injection will increase drug transport between organ sys-
tems according to a complex interplay of tissue drug affin-
ity, relative concentration, and perfusion. As such, net
movement of intoxicant may not prove universally benefi-
cial (that is, from target organ to peripheral depot). For
example, in one study investigating the effect of ILE on
thiopental anaesthesia in rabbits, early lipid administration
appeared to increase the depth, but not overall duration,
of anaesthesia. This could be explained by the action of
lipid emulsion as a high affinity conduit - maintaining
blood concentrations able to interact with the brain dur-
ing early redistribution to hydrophilic tissues, before aug-
menting later redistribution from rapidly perfused to
lesser perfused lipophilic tissues [41].
Perhaps most vexing is the issue of ILE administration
following enteric overdose. Data suggesting that ILE in-
jection may actually augment absorption of lipophilic
toxins from the gastrointestinal lumen have emerged,
with increased mortality reported when ILE was admin-
istered early in the course of oral amitriptyline and ver-
apamil toxicity [42], and earlier death following ILE in
rectal thiopentone overdose [43] in rodent models. Doc-
umented increases in plasma intoxicant concentrations
were reported in both studies. Effects on enhanced
gastrointestinal uptake are likely to be limited to the ab-
sorptive phase of intoxication. For example, when ILE
was administered 5 minutes after oral poisoning with
the lipophilic organophosphate parathion in rats, no dif-
ference was observed in time to respiratory arrest. When
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intravenous parathion concentration), ILE effected a sig-
nificant increase in survival times, consistent with bene-
ficial augmentation of drug redistribution [44].
The sum of what is known on the pharmacokinetic ef-
fects of ILE as antidote seems to be that there are demon-
strable effects on absorption, distribution and redistribution
for lipophilic intoxicants. Early ILE use in enteric poisoning
may be contraindicated because of potential for enhancing
gastrointestinal absorption, albeit any such adverse effect
is likely dependent on adequate intestinal perfusion, and
mitigated somewhat by development of shock-like states
secondary to intoxication. The clinical corollary of this
would be that effects on blood concentrations following
ILE administration likely depend on the timing of admin-
istration relative to both the pharmacokinetic phase and
the mode of intoxication. It would also seem prudent to
ensure actions necessary to mitigate gastrointestinal ab-
sorption, such as activated charcoal, were taken before or
contemporaneous to lipid emulsion.
Direct cardiotonic effect
While clinical and experimental effects spanning agents
and organ systems favour a pharmacokinetic mechanism
as important in the action of ILE, they are not a complete
explanation. Recent data have emerged that suggest lipid
emulsions at the doses used have direct cardiotonic ef-
fects. Experimentally, rats infused with lipid emulsion
showed increased blood pressure and aortic flow rates
relative to the same volume of saline. Additionally, iso-
lated rat hearts in isovolumetric contraction were seen to
contract more forcefully, with increased oxygen demand,
when perfusate was augmented with lipid emulsion [45].
Stehr and colleagues [46] additionally demonstrated a
positive effect on bupivacaine toxic cardiac myocytes at
levels below those that could have effected any 'sink'
phenomenon. The same investigators furthermore mod-
elled the relative contributions of volume, sink and cardio-
tonic effects in an in silico model for the observed effect
on recovery of rats from bupivacaine-induced shock. The
model of best fit included all three factors, with the direct
cardiotonic effect being the most prominent factor re-
sponsible for observed improvement [47].
It seems likely that direct cardiotonic effects play a
significant role as one of the mechanisms responsible
for resuscitation from drug-induced cardiotoxicity. This
may be particularly so in the arrested or critically com-
promised circulation in order to offer immediate support
before any distributive effects are likely to occur.
Fatty acid metabolism theory
There is evidence that metabolic pathways influenced by
lipid emulsion are important in the experimental mech-
anism of action of ILE. Partownavid and colleagues [48]demonstrated failure of ILE rescue in rat bupivacaine
toxicity in the presence of the inhibitor of fatty acid me-
tabolism CTV. A dose-dependent relationship for CTV
on both resuscitation outcome and measures of cardiac
function post-resuscitation was additionally observed. In
an associated laboratory experiment, bupivacaine toxic
mitochondria were more resistant to external calcium
pulses, thought to be a mechanism effecting cell death,
when treated with ILE prior to extraction. Conversely,
Bania and colleagues [49] reported no adverse effect for
oxfenicine, a blocker of fatty acid transport into mito-
chondria, on survival time during verapamil infusion in
whole rats.
While experimental data showing reduction in myocar-
dial bupivacaine concentration post-ILE demonstrate that
pharmacokinetic mechanisms play a role in ILE resuscita-
tion, these metabolic experiments are compelling that
metabolic and cardiotonic considerations are at least a
necessary, if not sufficient, mechanism of action in ex-
perimental bupivacaine toxicity. This, in concert with
the data on direct cardiotonic effects, is particularly
important in the clinical development of ILE as anti-
dote, as it suggests that pharmacokinetic testing alone
will tend to incompletely evaluate the potential for
antidotal action of ILE. Metabolic factors may further-
more hold differential importance depending on the
toxic compound.
Ion channel modulation theory
Free fatty acids, the levels of which increase with ILE,
are known to have effects on both sodium and calcium
ion channel function. Arachidonic, linoleic and linolenic
acid all increased calcium currents through activated cal-
cium channels in isolated guinea pig cardiac myocytes
[50]. This effect appears to be directly on the channel,
not modulated by any cellular second messenger system.
Such an effect could be particularly important in ameli-
orating toxicity from calcium channel blockers, and
could potentially be responsible for the short, direct car-
diotonic effect seen with ILE.
Mottram and colleagues [51] demonstrated that stearic
acid partially antagonises cultured human voltage-gated
sodium channels. This antagonist effect was shown
experimentally to partially reverse the sodium channel
antagonism seen with bupivacaine. Nadrowitz and col-
leagues [52] have also demonstrated partial reversal of
bupivacaine-induced sodium channel antagonism on the
Nav15 sodium channel, known for particular tropism
with bupivacaine, with lipid application in cultured hu-
man kidney cells. Notably, in cases where lipid emulsion
has been reported as having a positive outcome as an
antidote, sodium channel antagonists are prominent in-
toxicants [18-22], and very rapid resolution of QRS dur-
ation is often reported.
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Human trials
Few investigators have studied ILE in human popula-
tions. Taftachi and colleagues [53] reported the use of a
lipid emulsion preparation in a randomised trial evaluat-
ing the effect on conscious state in drug-induced coma.
In addition to standard supportive care, 15 patients were
given an infusion of 10 ml/kg 10 % lipid emulsion. A sta-
tistically significant increase in Glasgow Coma Scale
(GCS) of 2 points was seen in the ILE group. No re-
ported differences were seen for rates of intubation (the
primary powered endpoint) or time to extubation. This
study has a number of methodological flaws limiting
generalisability, including absence of a control solution,
and no blinding in acquisition of key study metrics
(GCS). Additionally, the study tested a number of end-
points without statistical correction for repeat analysis.
Perhaps the greatest contribution of this work is in dem-
onstrating that trials involving ILE in toxicology are
feasible.
Gil and colleagues [54] evaluated the effect of ILE on
glyphosate intoxication. After a positive case report,
their institution began treating glyphosate intoxication
with ILE along with supportive care from January 2012.
A two-tiered approach to ILE administration was taken,
with those ingesting less than 100 ml of herbicide
thought to be at lesser risk of toxicity and given 20 ml/
hour of 20 % lipid emulsion, and those ingesting more
than 100 ml of herbicide treated with a load of 500 ml
of 20 % lipid emulsion over 2 to 3 hours and then main-
tained on 42 ml/hour for the next 24 hours. Historical
controls were taken from the previous 2 years of prac-
tice, matched for volume and timing of ingestion.
Twenty-two cases and controls were compared, with 13
higher dose intoxicant patients in each group. No
hypotension or arrhythmia was seen in the ILE-treated
group versus rates of 40.9 % (hypotension) and 22.7 %
(arrhythmia) in the control group. These differences
reached statistical significance. The preponderance of
hypotension and arrhythmia was seen in controls who
ingested higher doses of intoxicant. Additionally, death
(one case) and acute kidney injury (three cases) were
seen only in the control group, and the rate of respira-
tory failure was lower in the ILE group (14 % versus
32 %), although these differences did not reach statistical
significance. It is considered most likely that surfactants
associated with the herbicide are responsible in large
part for toxic action, and the authors postulated some
sink mechanism may have been in action to ameliorate
toxicity.
Case series
The LIPAEMIC investigators reported 48 cases of use of
ILE where details of intoxicant, treatment and outcomewere entered into an online registry. Complete capture
of all cases treated in contributing centres was unlikely
based on declining reporting rates over the time of data
collection, meaning that inherent positive publication
bias in case reports and series may still have been acting
on this dataset. Increases were seen over a short time-
span in both GCS in cases where lipid was used for al-
tered conscious state (median GCS increasing from 4 to
8 over 30 minutes) and systolic blood pressure in
shocked patients (median systolic pressure increasing
from 70 to 90 mmHg over 30 minutes). One serious
complication (bronchospasm) and two minor adverse ef-
fects were recorded. Given the nature of data collection,
these results hold significance as contributors to hypoth-
esis generation [55].
The ToxIC consortium reported a case series of nine
uses of ILE from three tertiary referral centres [56]. Indi-
cations for use were post-cardiac arrest or refractory
shock defined as circulatory compromise requiring the
use of more than one vasopressor. Five of the nine pa-
tients survived, which was considered a positive out-
come for ILE.
Three case series have been reported as conference ab-
stracts. The Washington poisons centre reported five
cases of use [57]: bupivacaine toxicity (asystole), and
carbamazepine, hydroxychloroquine, flecainide and bu-
propion toxicity (seizures and hypotension). All cases
were associated with clinical resolution of acute effects.
Kapadia and colleagues [58] reported two cases of tricyc-
lic antidepressant toxicity refractory to maximal therapy
including alkalinisation and hypertonic saline whose
clinical course improved after ILE. Jovic-Stosic and col-
leagues [59] reported a series of nine uses of ILE where
the indication for use was poor response to vasopressors
in a series of patients intoxicated with a lipophilic toxin.
Increases in blood pressure and GCS, reported as occur-
ring in all patients, were not quantified. A decrease in
free verapamil concentration was described in one pa-
tient after ILE, with this same patient also exhibiting evi-
dence of acute respiratory distress syndrome.
Case reports
Two recent publications have summarised individual
cases reported in the literature [8,10]. Case report data
can be instructional in offering insights into therapies,
and are particularly useful when outlining an 'all or
nothing' type clinical situation. The significant limitation
of such analyses is that for any effect published - both
positive and negative - it is not known how many un-
published cases were treated. The absence of an accurate
numerator significantly limits the generalisability of such
collections of cases. With this as a major caveat, the
review of Waring [10] found that there was reported
improvement in 51 of 76 cases following administration
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LAST, 26 % being cardiovascular drugs, 25 % psycho-
tropic agents and 11 % antiepileptic).
Controversies
Porcine models in lipid resuscitation
Studies investigating ILE as antidote that report nega-
tive results in animal models have mainly used the por-
cine model. Swine are known to be more prone to
complement-mediated allergic type reactions with lipo-
somal formulations, and this may be important in nega-
tive studies involving ILE. Weinberg and Rubinstein
[60] surveyed all the authors of papers using the porcine
model for ILE/antidote research and found a majority
noted skin discoloration in the ILE-treated subjects
consistent with such an anaphylactoid phenomenon.
Two of 10 lipid treated pigs in a protocol investigating
amitriptyline distribution required adrenaline boluses,
despite baseline haemodynamics having returned to
normal before study treatment and end-myocardial
levels of amitriptyline being lower in the lipid-treated
group [36]. What data are available on ILE as antidote
do not appear to indicate that such reactions have oc-
curred in humans.
Vasopressor coadministration with intravenous lipid
emulsion in local anaesthetic systemic toxicity
Literature reports of vasopressor administration in con-
cert with ILE-based resuscitation from local anaesthetic
induced cardiac arrest in animal models have returned
conflicting findings. In 2009, Hiller and colleagues [61]
demonstrated that epinephrine impaired resuscitation
from bupivacaine-induced asystole in rats in a dose-
dependent fashion. Epinephrine injection was associated
with elevated serum lactate, acidosis, and lesser haemo-
dynamic recovery. Similarly, in earlier work Weinberg
and colleagues [62] demonstrated the superiority of ILE
over both epinephrine and a vasopressin/epinephrine
combination [63] in rodent models of bupivacaine-
induced cardiac arrest. Conversely, Mayr and colleagues
[64] demonstrated superior recovery with vasopressors
alone in a swine model of bupivacaine-induced cardiac
arrest; albeit induction of cardiac arrest was accompan-
ied by significant hypoxia. Mauch and colleagues [65]
furthermore reported lesser recovery from bupivacaine-
induced shock with ILE alone compared with adrenaline,
and greater return of spontaneous circulation and sur-
vival in piglets receiving adrenaline with or without ILE
in bupivacaine-induced cardiac arrest. Administration of
high dose (100 mcg/kg) adrenaline in concert with ILE
in bupivacaine-induced cardiac arrest has almost univer-
sally resulted in deleterious outcome in animal models.
What appears clear is that avoidance of hypoxia (known
to exacerbate local anaesthetic toxicity), and ensuringadequacy of cardiopulmonary resuscitation (and thereby
coronary perfusion) is essential in effecting recovery.
Omission of vasopressors, and adrenaline in particular,
from resuscitation algorithms in LAST at this juncture
remains controversial.
Potential interaction with other resuscitation drugs
The generic nature of the sink hypothesis in ILE-based
resuscitation from toxin-induced cardiac arrest has led
some to question potential interaction with therapeutic-
ally administered lipophilic drugs. It would seem appar-
ent that any effect on redistribution of toxic agents
might also likewise affect agents administered therapeut-
ically. ILE has been shown to sequester amiodarone in
plasma, and ameliorate its hypotensive action when
given in overdose in whole pigs [32]. The clinical effect
of potential ILE-mediated pharmacokinetic modulation
on therapeutically administered pharmaceuticals, how-
ever, remains uncertain. There are no direct published
data on the relative roles of ILE and extracorporeal life
support, with decisions to do with the use of ILE when
extracorporeal life support is available in a timely fash-
ion being necessarily based on clinical judgement.
Enteric overdose
In keeping with the pharmacokinetic theory of ILE’s mech-
anism, increased gastrointestinal absorption of lipophilic
intoxicant might be predicted with ILE use as blood with
increased affinity for highly soluble xenobiotics perfuses in-
testinal mucosa. ILE administration early in the course of
enteric overdose may thereby paradoxically serve to in-
crease gut absorption and speed development of systemic
toxicity. While data in support of this are still emerging
[42-44], significant caution should be exercised when con-
sidering ILE administration early in the course of life-
threatening enteric overdose and steps should be taken
prior to use of ILE to ensure absorption is minimised.
Safety
Administration of ILE for its antidotal effect remains an
‘off-label’ indication. Much of what is known about ILE
toxicity is derived from historic studies of use in parenteral
nutrition situations. When administered for this indica-
tion, allergic phenomena, pancreatitis, induced bacter-
aemia, fat embolism, and myocardial failure are possible.
Few reports of adverse events when administered in the
context of life-threatening poisoning exist, with hyperamy-
lasaemia [66], and adult respiratory distress syndrome
being reported [5]. Lipaemia-induced impairment in la-
boratory processing [67] may hold considerable clinical
significance, particularly for patients for whom laboratory
data are pertinent to management, such as alkalinised tri-
cyclic toxic patients. Early toxicity evaluation in rodents
demonstrating a median lethal dose (LD50) of 67.72 ml/kg
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for a wide therapeutic margin [68]. Further reporting of
safety data is nevertheless required before final safety rec-
ommendations can be formalised.
Clinical implications
The sporadic and unpredictable nature of LAST renders
randomised controlled study of ILE in this setting diffi-
cult to impossible. The level of evidence available - ani-
mal models and case data - is supportive of effect and
not likely to be increased. Reflecting this, ILE has been
incorporated into LAST practice guidelines of governing
bodies for anaesthetists worldwide [14].
Typical administration regimes recommend initial
bolus injection of 1.5 ml/kg 20 % lipid emulsion followed
by an infusion of 15 ml/kg/hour with accommodation
for additional boluses to be given at 5 minute intervals.
A recommendation not to exceed 12 ml/kg ILE has been
proposed. Defining maximum length of treatment has
not been explored in depth, although there is an isolated
reported case where low dose lipid was used for some
days [69].
Recommendation of ILE use in non-local anaesthetic
drug poisoning remains controversial. While the present
review outlines that the level of evidence in this area is
evolving, the weight of evidence remains the same as in
the field of local anaesthetics. Such a level of evidence
can rationally be extended to the clinical situation of the
patient in extremus, but extending any recommendation
beyond this situation would require further human
study. Furthermore, the pharmacokinetic consideration
for ILE potentially exacerbating toxicity early in the
course of enteric overdose necessitates proceeding with
caution. ILE has been suggested as reasonable by the
American College of Medical Toxicology, American
Heart Association, and European Resuscitation Council
for patients exhibiting intractable haemodynamic in-
stability, or overt arrest, secondary to lipophilic drug
toxicity that has proven refractory to available therapies.
In this instance administration of ILE in accord with
guidelines for use in LAST appears reasonable. It is the
opinion of the authors that, at present, ILE utilisation
for the purpose of reversal of drug-induced coma cannot
be recommended outside the confines of a randomised
clinical trial.
Future research
Human randomised trials are possible in this field and
necessary to evaluate whether ILE has a more general
role in treatment of intoxicated patients. Registry data
aimed at capture of all instances of ILE application are
also required to determine an accurate denominator of
ILE use, such that clinical performance characteristics
may be inferred. Similarly, safety data in humans cannotbe derived unless all cases of ILE use and outcomes are
collated to central registries as significant adverse events
may occur rarely and require many thousands of uses to
identify.
Basic science experimentation is furthermore required
to delineate optimal doses and formulations of ILE for
human application. Research exploring the utility of li-
posomal detoxification vesicles has proven informative,
with engineered liposomes demonstrating ability to se-
quester lipophilic toxins with far greater affinity than
standard ILE in vitro [70]. Subsequent use in animal
models has shown the ability of such formulations to ef-
fect meaningful recovery [71].
Conclusion
Recent advances in understanding the mechanism of ILE
treatment in poisoning suggest ion channel, metabolic
and cardiotonic effects are of importance along with the
more frequently quoted pharmacokinetic (sink) theory.
While the evidence base for ILE use in acute drug in-
toxication is evolving, the present evidence supports use
of ILE only in LAST and in lipophilic cardiotoxin intoxi-
cation when there is an immediate threat to life, and
other therapies have proven ineffective.
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